12/13
01:10 am
immx
Immix Biopharma (NASDAQ:IMMX) was upgraded by analysts at
Wall Street Ze
High
Report
Immix Biopharma (NASDAQ:IMMX) was upgraded by analysts at
Wall Street Ze
12/11
12:11 am
immx
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition [Seeking Alpha]
Medium
Report
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition [Seeking Alpha]
12/9
05:45 pm
immx
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
12/9
09:11 am
immx
Immix Biopharma (NASDAQ:IMMX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Immix Biopharma (NASDAQ:IMMX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/7
06:20 pm
immx
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
12/7
06:15 pm
immx
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Medium
Report
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
11/12
09:13 am
immx
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch [Yahoo! Finance]
High
Report
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch [Yahoo! Finance]
11/12
09:00 am
immx
Immix Biopharma appoints Michael Grabow as chief commercial officer to drive NXC-201 launch [Seeking Alpha]
High
Report
Immix Biopharma appoints Michael Grabow as chief commercial officer to drive NXC-201 launch [Seeking Alpha]
11/12
08:45 am
immx
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
High
Report
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
11/3
08:45 am
immx
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
Medium
Report
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
10/14
08:45 am
immx
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Low
Report
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
10/8
12:25 pm
immx
Immix Biopharma (NASDAQ:IMMX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Immix Biopharma (NASDAQ:IMMX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/6
04:47 pm
immx
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting [Yahoo! Finance]
High
Report
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting [Yahoo! Finance]
10/6
04:05 pm
immx
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
High
Report
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
10/1
08:45 am
immx
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
Low
Report
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference